Journal Article (Review Article)

DKFZ-2025-01110

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.

Teleanu, M.-V. (First author)DKFZ* ; Schneider, A.DKFZ* ; Ball, C.DKFZ* ; Leber, M. F.DKFZ* ; Stange, C.DKFZ* ; Krieghoff-Henning, E.DKFZ* ; Beck, K.DKFZ* ; Heilig, C. E.DKFZ* ; Kreutzfeldt, S.DKFZ* ; Kuster, B.DKFZ* ; Lipka, D.DKFZ* ; Fröhling, S. (Last author)DKFZ*

2025
MDPI Basel

This record in other databases:

Please use a persistent id in citations: doi:10.3390/biom15050693

Abstract: Precision oncology is becoming a mainstay in the standard of care for cancer patients. Recent technological advancements have significantly lowered the cost of various tumor profiling approaches, broadening the reach of molecular diagnostics and improving patient access to precision oncology. In parallel, drug development and discovery pipelines continue to evolve, driving targeted therapeutic options forward. Yet, not all patients harboring actionable molecular alterations respond to these interventions, and existing therapies do not cover the entire spectrum of potential molecular targets. In this review, we examine the current suite of omics technologies employed in clinical settings and underscore their roles in deepening our understanding of tumor biology and optimizing patient stratification for targeted treatments. We also highlight relevant precision oncology trials and share our own experiences using multi-omics data within a molecular tumor board framework. Finally, we discuss areas for future exploration aimed at propelling precision oncology to new heights.

Keyword(s): Humans (MeSH) ; Precision Medicine: methods (MeSH) ; Neoplasms: genetics (MeSH) ; Neoplasms: metabolism (MeSH) ; Neoplasms: drug therapy (MeSH) ; Neoplasms: therapy (MeSH) ; Genomics: methods (MeSH) ; Proteomics: methods (MeSH) ; Multiomics (MeSH) ; molecular profiling ; patient stratification ; precision oncology

Note: #EA:B340#LA:B340# / 2025 May 10;15(5):693

---

Contributing Institute(s):

1. Translationale Medizinische Onkologie (B340)
2. DKTK HD zentral (HD01)
3. DKTK Koordinierungsstelle München (MU01)
4. DKTK Koordinierungsstelle Dresden (DD01)
5. KKE Virotherapie (D490)
6. Personalisierte Medizinische Onkologie (A420)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---